Literature DB >> 20185273

Treatment options for 2009 H1N1 influenza: evaluation of the published evidence.

Matthew E Falagas1, Evridiki K Vouloumanou, Evagelia Baskouta, Petros I Rafailidis, Kostantinos Polyzos, Jordi Rello.   

Abstract

We evaluated the evidence regarding the effectiveness of various treatment strategies used for 2009 H1N1 influenza by reviewing available relevant studies. In total, 22 studies (15 cohort studies involving >10 patients, 5 cohort studies with < or = 10 patients and 2 case reports) were included. A total of 3020 patients [1068 (35.4%) critically ill, 1722 (57.0%) hospitalised and 230 (7.6%) outpatients, including 909 (30.1%) children] were involved. Notably, 487 (16.1%) were obese [body mass index (BMI) >30)], 362 (12.0%) had asthma or chronic obstructive pulmonary disease and 255 (8.4%) were pregnant. Antiviral treatment was administered to 1622 patients (53.7%), of whom 661 (40.8%) received oseltamivir monotherapy. Corticosteroids were administered in 323 (31.8%) of 1016 patients for whom relevant data were available. Similarly, 633 (85.0%) of 745 patients received antibiotics. Comparative data from the largest included study (involving 1088 patients) indicated that administration of antivirals within 2 days from symptom onset was significantly associated with reduced mortality (P<0.001). In summary, the scarcity of comparative available data hampered the establishment of any firm conclusions regarding the benefit that various treatment strategies may confer to patients with 2009 H1N1 influenza. Studies with a comparative design, as well as randomised studies are needed to clarify further this issue of major importance. Copyright 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185273     DOI: 10.1016/j.ijantimicag.2010.01.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  22 in total

Review 1.  Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review.

Authors:  Marinos C Makris; Konstantinos A Polyzos; Michael N Mavros; Stavros Athanasiou; Petros I Rafailidis; Matthew E Falagas
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic.

Authors:  Justin J O'Hagan; Karen K Wong; Angela P Campbell; Anita Patel; David L Swerdlow; Alicia M Fry; Lisa M Koonin; Martin I Meltzer
Journal:  Clin Infect Dis       Date:  2015-05-01       Impact factor: 9.079

3.  2009 Pandemic Influenza A (H1N1): Diagnosis, Management, and Prevention- Lessons Learned.

Authors:  Kristin A Swedish
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

4.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Authors:  Kevin B Walsh; John R Teijaro; Peter R Wilker; Anna Jatzek; Daniel M Fremgen; Subash C Das; Tokiko Watanabe; Masato Hatta; Kyoko Shinya; Marulasiddappa Suresh; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

Review 5.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

Review 6.  Corticosteroids for severe influenza pneumonia: A critical appraisal.

Authors:  Wagner Luis Nedel; David Garcia Nora; Jorge Ibrain Figueira Salluh; Thiago Lisboa; Pedro Póvoa
Journal:  World J Crit Care Med       Date:  2016-02-04

Review 7.  Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm.

Authors:  Kevin B Walsh; John R Teijaro; Hugh Rosen; Michael B A Oldstone
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 8.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

9.  Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009).

Authors:  J S Nguyen-Van-Tam; P J M Openshaw; A Hashim; E M Gadd; W S Lim; M G Semple; R C Read; B L Taylor; S J Brett; J McMenamin; J E Enstone; C Armstrong; K G Nicholson
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

10.  Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice.

Authors:  John C Kash; Yongli Xiao; A Sally Davis; Kathie-Anne Walters; Daniel S Chertow; Judith D Easterbrook; Rebecca L Dunfee; Aline Sandouk; Brett W Jagger; Louis M Schwartzman; Rolf E Kuestner; Nancy B Wehr; Karl Huffman; Rosalind A Rosenthal; Adrian Ozinsky; Rodney L Levine; Susan R Doctrow; Jeffery K Taubenberger
Journal:  Free Radic Biol Med       Date:  2013-10-17       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.